Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Trasylol aprotinin: Trial halted

BAY said the investigator-sponsored Canadian BART trial in about 3,000 high-risk cardiac

Read the full 128 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE